Recurrence ovary cancer presenting with scleroderma - a rare case report

Betul Sargin¹, Gulcan Gurer¹, Gulnur Tasci Bozbas², Fatih Noyan², Kayra Barut², Canten Tataroglu³

Abstract

Scleroderma is a chronic autoimmune multisystem disorder which is characterized by progressive fibrosis of the skin and internal organs. Ovary cancers with scleroderma have been reported in the literature. But recurrent ovary cancer with scleroderma has not been reported before. Here, we report a 65-year-old female patient presenting with recurrent ovary cancer and subsequently diagnosed with scleroderma. To the authors' knowledge, this is the first case of presenting with recurrent ovary cancer and scleroderma.

Keywords: recurrent, ovary cancer, scleroderma

Introduction

Scleroderma is a chronic autoimmune multisystem disorder which is characterized by progressive fibrosis of the skin and internal organs (1). This disorder develops in the 30–50s and occurs with the average incidence up to 0.002% (2). There are 3 subclasses of systemic scleroderma: limited cutaneous, diffuse cutaneous and sine scleroderma. Prognosis depends on the extent of organ involvement (3). Cutaneous associations of ovarian carcinoma are rare manifestations. These include acanthosis nigricans, Raynaud's phenomenon, scleroderma, dermatomyositis and palmar fasciitis with polyarthritis (4), disseminated superficial porokeratosis (5), multicentric reticulohistiocytosis (MR) (6) and leukocytoclastic vasculitis (7). Here, we report a 65-year-old female patient presenting with recurrent ovary cancer and subsequently diagnosed with scleroderma. In scanning literature, it was seen that recurrent ovary cancer and scleroderma has not been reported yet.

Case

A 65-year-old female patient presented with complaints of diffuse cutaneous sclerosis and thickening along with oedema in right lower limb since four months (Figure 1). She had a history of a serous papillary adenocarcinoma of the ovary. This was diagnosed 4 years prior to her presentation to our clinic and she had been treated adjuvant chemotherapy; paclitaxel and carboplatin. She underwent total abdominal hysterectomy (TAH) with bilateral salpingo-oophorectomy (BSO) and pelvic lymph node dissection. She had responded well to her treatment. On further questioning, she had noticed thickening and oedema in right lower limb. She did not have medical history about Raynaud’s phenomenon, sclerodactylia, pitting scars before. She had no history of smoke or alcohol consumption. The general condition was moderate, oriented and cooperated. Locomotor system examination revealed there was skin thickening in right lower limb. The patient’s laboratory findings are presented in Table 1. Doppler ultrasonography was normal. A skin biopsy was taken and the histology showed dermal sclerosis pathology was consistent with scleroderma (Figure 2). Due to the presence of dermal biopsy, acute-phase proteins including erythrocyte sedimentation rate, C-reactive protein and immunological tests including antinuclear antibody were investigated. These tests showed positive antinuclear antibody (ANA) (1: >100 granular and nuclear membrane), anti-Scl 70 antibody (2+). She was subsequently found to have an elevated carcinoma antigen 125 level of 190 units/ml and the patient was diagnosed as recurrent ovary cancer and scleroderma. Computed tomography (CT) of the chest, abdominal cavity and pelvis were normal with no metastases. She was started on prednisolone (32mg) and hydroxychloroquine (200mg) while her subsequent examinations took place. She was later started on paclitaxel chemotherapy for recurrent ovary cancer and until now has received two cycles. Following prednisolone and hydroxychloroquine treatment, her complaints of skin thickening and oedema in right lower limb were improved.
Table 1. Laboratory findings of the patient

<table>
<thead>
<tr>
<th></th>
<th>Values</th>
<th>Normal Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>13,3 gr/dl</td>
<td>11,7-15,5 gr/dl</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>40,4 %</td>
<td>37-44</td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>6,63 mkrl</td>
<td>3,800-11,000 mkrl</td>
</tr>
<tr>
<td>Platelet</td>
<td>216,000 mkrl</td>
<td>150,000-350,000 mkrl</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate</td>
<td>48 mm/h</td>
<td>0-20 mm/h</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>14,81 mg/l</td>
<td>0-6 mg/l</td>
</tr>
<tr>
<td>Urea</td>
<td>27 gr/dl</td>
<td>13-43 gr/dl</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0,80 mg/dl</td>
<td>0,7-1,3 mg/dl</td>
</tr>
<tr>
<td>ANA</td>
<td>1 : &gt;100 granular and nuclear membrane pattern</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-Scl 70</td>
<td>++ Positive</td>
<td>Negative</td>
</tr>
</tbody>
</table>

Figure 1: Right limb oedeme

Figure 2: Dermal edema, perivascular lymphocyte infiltration and collagen fibriler hyperplasia
Discussion

To the knowledge, this is the first case of recurrent ovary cancer presenting with scleroderma. Jedlickova et al. indicated 4 patients with paraneoplastic scleroderma who were diagnosed with cholangiocarcinoma, endometrial carcinoma, prostatic adenocarcinoma and adenoma of the suprarenal gland (8). Marek et al. noticed a case with scleroderma-like syndrome in the course of colorectal cancer (2). Several studies have suggested an increased risk of cancer in patients with systemic sclerosis, but the potential risk factors for these cancers remain unknown. Kyndt et al. announced among 123 patients with systemic sclerosis, 14 cases of cancer (11.3%) were found (lung n = 3, breast n = 2, ovarian n = 2, skin n = 1, thyroid n = 1, rectum n = 1, uterine cervix n = 1, larynx n = 1, pancreas n = 1, myelodysplasia n = 1) (9). Bielefeld et al. reported 21 cases of the association systemic scleroderma and cancer. (lung n = 5, breast n = 2, oesophagus n = 1, stomach n = 1, colon n = 1, uterus n = 4, ovarian n = 1, prostatic n = 1, renal n = 1 and malignant hemopathies n = 6) (10). Bielefeld et al. stated that since 1886, more than three hundred cases of such an association have been reported; essentially lung cancers (more than 100) and epidemiological studies concluded a higher frequency of lung and breast cancers (10). In the literature, we found 27 case-reports exposing the co-existence systemic scleroderma and cancer after this review. Case reports about association of scleroderma and ovary cancer are available in literature (11-16). Su et al. presented a 53-year-old woman with systemic sclerosis and Meigs’ syndrome (pleural effusion, ascites and an ovarian tumour) (17). In scanning literature, co- existence of scleroderma and ovary cancers were presented, although recurrent ovary cancer that were presented with scleroderma has not been reported. Also, case reports developing cancer after scleroderma diagnoses were informed. But, recurrent cancer development presenting with scleroderma as in our case is not common. Reynolds et al. announced a 44-year-old woman with a history of recurrent metastatic breast cancer presenting with paraneoplastic scleroderma (18). Findings of our patient didn’t support paraneoplastic scleroderma. Because, a serous papillary adenocarcinoma started 4 years ago, her laboratory analysis showed anti-Scl 70 antibody positive and she responded good to standard treatment. In the literature, our patient is second case recurrent cancer presenting with scleroderma. Moreover, our patient is first case recurrent ovary cancer presenting with scleroderma.

Conclusion

We suggest that cutaneous associations of ovarian cancer or other other malignities should be carefully followed until a final diagnosis can be clearly made. When cutaneous lesion develops in patients who have cancer history, the possibility of recurrent cancer should be kept in mind and the patients should be examined in this respect.

Acknowledgments: This prospective study was performed at Sehitkamil Government Hospital, Gaziantep, Turkey

Ethical issues: All Authors declare that Originality of research/article etc... and ethical approval of research, and responsibilities of research against local ethics commission are under the Authors responsibilities. The study was conducted due to defined rules by the Local Ethics Commission guidelines and audits.

References


